drugset / Trial / NCT03371329

Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage

NCT03371329

Phase 1 Completed 9 enrolled Mayo Clinic
Non-randomizedSequentialOpen-labelTreatment

Summary

The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of acute spontaneous hemorrhagic stroke.

Timeline

Start
2017-12-12
Primary completion
2020-10-09
Completion
2020-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy 0.5 cells/kg Intravenous
Subject Mesenchymal stem cell Cell therapy 1 cells/kg Intravenous
Subject Mesenchymal stem cell Cell therapy 2 cells/kg Intravenous